Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,773
  • Shares Outstanding, K 25,615
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,000 K
  • EBIT $ -26 M
  • EBITDA $ -26 M
  • 60-Month Beta -0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.76

Options Overview Details

View History
  • Implied Volatility 294.37% (-191.29%)
  • Historical Volatility 59.78%
  • IV Percentile 76%
  • IV Rank 39.61%
  • IV High 684.74% on 11/07/25
  • IV Low 38.36% on 09/05/25
  • Expected Move (DTE 13) 0.13 (1.90%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 77
  • Volume Avg (30-Day) 106
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 5,869
  • Open Int (30-Day) 4,994
  • Expected Range 6.58 to 6.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.31
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +30.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.55 +20.90%
on 11/07/25
6.84 -1.90%
on 12/05/25
+1.06 (+18.76%)
since 11/05/25
3-Month
5.55 +20.90%
on 11/07/25
7.00 -4.14%
on 10/29/25
+0.03 (+0.45%)
since 09/05/25
52-Week
4.44 +51.13%
on 12/23/24
11.52 -41.75%
on 04/28/25
+1.95 (+40.97%)
since 12/05/24

Most Recent Stories

More News
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision...

NVCT : 6.71 (-0.52%)
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation...

NVCT : 6.71 (-0.52%)
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases;...

NVCT : 6.71 (-0.52%)

Business Summary

Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.

See More

Key Turning Points

3rd Resistance Point 7.07
2nd Resistance Point 6.96
1st Resistance Point 6.83
Last Price 6.71
1st Support Level 6.59
2nd Support Level 6.48
3rd Support Level 6.35

See More

52-Week High 11.52
Fibonacci 61.8% 8.82
Fibonacci 50% 7.98
Fibonacci 38.2% 7.14
Last Price 6.71
52-Week Low 4.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar